Document is current
Any future updates will be listed below
-
Authors
Shewell, Lucy K.
Day, Christopher J.
Kutasovic, Jamie R.
Abrahams, Jodie L.
Wang, Jing
Poole, Jessica
Niland, Colleen
Ferguson, Kaltin
Saunus, Jodi M.
Lakhani, Sunil R.
von Itzstein, Mark
Paton, James C.
Paton, Adrienne W.
Jennings, Michael P. http://orcid.org/0000-0002-1027-4684
-
Funding
Funding for this research was provided by:
national health and medical research council (1071659, 1084050, 1138466, APP1113867)
u.s. department of defense (W81XWH-20-1-0527)
royal brisbane and women's hospital foundation
- License Information
-
More Information
Article History
Received: 2 August 2021
Accepted: 20 March 2022
First Online: 26 March 2022
Declarations
:
: The patient data and serum samples used in this project were provided by the Victorian Cancer Biobank with informed consent from all donors and use of the samples was approved by the Griffith University HREC (GU Ref No: 2017/732). Human research ethics committees of The University of Queensland (ref. 2005000785) and The Royal Brisbane and Women’s Hospital (2005/022) approved the Circ.BR study with written informed consent obtained from each subject.
: Not applicable.
: The following authors (JCP, AWP, CJD and MPJ) declare that they are named inventors on a patent on the SubB2M technology (WO2018085888A1) and a second patent (JCP, AWP, CJD, LKS and MPJ) for improvements to the SubB2M test (2021901444). Both of these patents were licensed to BARD1 Life Sciences (now Inoviq), VIC, Australia in 2020.
